
Abalone Bio YC Application
Abalone Bio went through Y Combinator in the Winter 2020 batch as a Healthcare company. Below: what the company does, who founded it, and its application to YC, reconstructed question by question in the real YC form.
- YC batch
- Winter 2020
- Industry
- HealthcareDrug Discovery and Delivery
- Team size
- 14
- Status
- Active
- Launched
- 2020
Founders
Richard YuFounder
Gustavo PesceFounder
What Abalone Bio does
Abalone Bio is tackling challenging undrugged targets underlying diseases affecting millions, focusing first cell-specific antibody drugs to treat obesity and metabolic disease without the GI side effects that cause 25% of GLP-1 drug patients to quit after 1 year. + High throughput experimental measurement uniquely leverages AI/ML: We’ve engineered cells to measure antibodies for pharmacological activity, not just structure or binding like others, 100 million at a time, 100X+ the throughput of others. With our large, proprietary activity datasets, we uniquely leverage ML to both unlock the discovery of rare hits and generate optimized hits for challenging targets, starting with G-protein coupled receptors (GPCRs) + Proven success: We have developed antibody agonists (activators) for 2 out of the 8 G-protein coupled receptors ever drugged by biotech. + Pharma traction: We’ve secured 3 partnerships with $3M in revenue and $125M in downstream value. + Externally validated science: We’ve been awarded $7M in non-dilutive grant funding for platform and program development.
Abalone Bio's YC application, reconstructed
Y Combinator application
Abalone Bio, Winter 2020 batch. The real form questions, answered from public data.
- Founders2
- Company7
- Progress7
- Idea4
- Equity3
- Curious2
- Batch Preference1
Company
Abalone Bio
We create activating antibodies to treat diseases others can't.
We build a platform that combines high-throughput experimental antibody screening with machine learning to discover activating antibodies targeting cell-specific receptors. Our product enables discovery and optimization of rare antibody hits against challenging targets like GPCRs, starting in obesity and metabolic diseases, focusing on safety and efficacy beyond current drugs.
We live in San Francisco, CA, and the company is based here.
San Francisco is a hub for biotech and AI talent, which is critical for our platform combining synthetic biology and machine learning. Being in SF keeps us close to partners and investors focused on healthcare innovation.
21 more answers in the full application
Founders, Progress, Idea, Equity, Curious, Batch Preference are in the full version. Create a free account to open it in YC Insights, next to every other YC batch.
Frequently Asked Questions
Is this the real Abalone Bio YC application?
No. Y Combinator keeps submitted applications private. This is a reconstruction: the real YC form questions, answered from Abalone Bio's public data (launch notes, founder backgrounds, product description). It shows how a company like Abalone Bio would present itself to YC, not the text they submitted.
What YC batch was Abalone Bio in?
Abalone Bio was part of the Y Combinator Winter 2020 batch.
Who founded Abalone Bio?
Abalone Bio was founded by Richard Yu, Gustavo Pesce.
What does Abalone Bio do?
We create activating antibodies to treat diseases others can’t.
How do I read the full reconstructed application?
Create a free Round Funded account. The full 26-answer version of Abalone Bio's application, and every other YC batch, is in YC Insights.